Literature DB >> 27162793

Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis.

Parth K Modi1, Eric A Singer1.   

Abstract

Papillary renal cell carcinoma (pRCC) is a heterogeneous and incompletely understood histologic subtype of kidney cancer. Recently, authors from The Cancer Genome Atlas Research Network performed a comprehensive molecular characterization of pRCC. Using multiple analytic methods, they identified 4 subgroups of pRCC with varied genotypic anomalies and probabilities of overall survival. This analysis elucidated the differences between type 1 and type 2 pRCC. Furthermore, type 2 pRCC was found to be heterogeneous itself, with at least 3 subtypes with distinct molecular features. This improved characterization and insight about potential driver mutations and altered pathways may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC.

Entities:  

Keywords:  Kidney cancer; clear cell; genomic; non-clear cell; papillary; renal cell carcinoma (RCC)

Year:  2016        PMID: 27162793      PMCID: PMC4842405          DOI: 10.21037/atm.2016.03.43

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  24 in total

Review 1.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

2.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 4.  Targeted therapies for non-clear renal cell carcinoma.

Authors:  Eric A Singer; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Target Oncol       Date:  2010-08-03       Impact factor: 4.493

5.  Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Authors:  Robert J Motzer; Bernard Escudier; Stephane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Andrea Kay; Alain Ravaud
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

6.  The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.

Authors:  Wing-Hang Tong; Carole Sourbier; Gennady Kovtunovych; Suh Young Jeong; Manish Vira; Manik Ghosh; Vladimir Valera Romero; Rachid Sougrat; Sophie Vaulont; Benoit Viollet; Yeong-Sang Kim; Sunmin Lee; Jane Trepel; Ramaprasad Srinivasan; Gennady Bratslavsky; Youfeng Yang; W Marston Linehan; Tracey A Rouault
Journal:  Cancer Cell       Date:  2011-09-13       Impact factor: 31.743

7.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

Authors:  Michael S Gordon; Michael Hussey; Raymond B Nagle; Primo N Lara; Philip C Mack; Janice Dutcher; Wolfram Samlowski; Joseph I Clark; David I Quinn; Chong-Xian Pan; David Crawford
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

8.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Authors:  Toni K Choueiri; Ulka Vaishampayan; Jonathan E Rosenberg; Theodore F Logan; Andrea L Harzstark; Ronald M Bukowski; Brian I Rini; Sandy Srinivas; Mark N Stein; Laurel M Adams; Lone H Ottesen; Kevin H Laubscher; Laurie Sherman; David F McDermott; Naomi B Haas; Keith T Flaherty; Robert Ross; Peter Eisenberg; Paul S Meltzer; Maria J Merino; Donald P Bottaro; W Marston Linehan; Ramaprasad Srinivasan
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

9.  Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.

Authors:  Christopher B Allard; Francisco Gelpi-Hammerschmidt; Lauren C Harshman; Toni K Choueiri; Izak Faiena; Parth Modi; Benjamin I Chung; Ilker Tinay; Eric A Singer; Steven L Chang
Journal:  Urol Oncol       Date:  2015-07-22       Impact factor: 3.498

10.  PD-L1 expression in nonclear-cell renal cell carcinoma.

Authors:  T K Choueiri; A P Fay; K P Gray; M Callea; T H Ho; L Albiges; J Bellmunt; J Song; I Carvo; M Lampron; M L Stanton; F S Hodi; D F McDermott; M B Atkins; G J Freeman; M S Hirsch; S Signoretti
Journal:  Ann Oncol       Date:  2014-09-05       Impact factor: 32.976

View more
  3 in total

1.  Renal cell carcinoma: the search for a reliable biomarker.

Authors:  Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal:  Transl Cancer Res       Date:  2017-06       Impact factor: 1.241

2.  Renal cell carcinoma: molecular characterization and evolving treatment paradigms.

Authors:  Mark W Ball; Eric A Singer; Ramaprasad Srinivasan
Journal:  Curr Opin Oncol       Date:  2017-03-01       Impact factor: 3.645

3.  Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis.

Authors:  Zhongshi He; Min Sun; Yuan Ke; Rongjie Lin; Youde Xiao; Shuliang Zhou; Hong Zhao; Yan Wang; Fuxiang Zhou; Yunfeng Zhou
Journal:  Oncotarget       Date:  2017-04-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.